News
Yasir Al-Siraj, a Ph.D. candidate in the University of Kentucky College of Medicine Department of Pharmacology and Nutritional Sciences, is the lead author of a paper published in Circulation, a leading journal on cardiovascular medicine.
The article, “Female Mice with an XY Sex Chromosome Complement Develop Severe Angiotensin II-Induced Abdominal Aortic Aneurysms,” was co-authored by UK colleagues Sean E. Thatcher, Richard Charnigo, Kuey Chen, Eric Blalock, Alan Daugherty and Lisa Cassis.
LEXINGTON, Ky. (Dec. 14, 2016) —
"also.... just because
I am working out the flavor for the
1812 Overture
I will most likely put it into a lolli
this is an incredible challenge
as it is making me cry while I listen…"
Taria Camerino's poetic email sums up her passion for helping people explore how flavor perception is influenced by more than the tongue. Her emotion is genuine: as a gastral synesthete, she experiences ALL senses as taste.
An updated, “version 2.0” of the Electronic Internal Approval Form (eIAF), developed by UK’s Office of Sponsored Projects Administration (OSPA) and Enterprise Architecture Group (EAG), is in the final stages of testing. The updated form will have many improvements, including enhanced validation checks and the ability to view attachments in the same window as the eIAF.
We are changing over to a new streamlined online scheduling system for all instruments in the Light Microscopy Core. Please register at: http://rfom.ad.uky.edu/fom/register.
We are pleased to announce that the Office of Sponsored Projects Administration (OSPA) has a new staff member, John Craddock. John joins the staff under the auspices of the Vice President for Research with the goal of proactively streamlining compliance for UK investigators seeking funding that may be regulated by export control laws. John has worked as a Principal Investigator at the Center for Applied Energy Research on several export controlled projects where he developed protocols to remain in compliance with U.S. export control laws.
The Office of Sponsored Projects Administration, the Proposal Development Office, the Office of Research Integrity–IRB, the Survey Research Center and the COM Sponsored Research Administrative Services offices will be closed Monday, December 26, 2016 through Monday, January 2, 2017 and will reopen on Tuesday, January
The Final Research Performance Progress Report (F-RPPR) will replace the Final Progress Report (FPR) for grants closeout, effective January 1, 2017. The F-RPPR will be available for use in eRA Commons on January 1, 2017.
NOTE: For small businesses, the new F-RPPR will be in effect at least 2 months later, due to the unique final reporting requirements that they face under the SBIR/STTR policy directive.
For faculty members who are working with industry sponsors (non-clinical trial) for their research projects, please contact your COM Sponsored Research Administrative Services (SRAS) Grants Proposal Specialist (GPS), who can assist you during the time that you are negotiating your budget figures with the sponsor. Your GPS can assist with:
Answering your questions about what costs are allowable on industry-sponsored agreements.
John Gensel, an assistant professor in the physiology department and the Spinal Cord and Brain Injury Research Center, and two members of his lab team—Bei Zhang and Taylor Otto—are featured in this podcast.
Taylor Otto, an undergraduate lab assistant in Gensel’s lab, described UK as being the full package. “We have it all here. It’s a good program to be able to come into, not really knowing what you want to exactly do in the science field, but being able to figure it out at the same time,” said Otto.
In the spring of 2016, the University of Kentucky hired Dr. Robert DiPaola as the new dean for the UK College of Medicine. He had previously been the director of the Rutgers Cancer Institute of New Jersey and vice chancellor for cancer programs at the Rutgers Biomedical and Health Sciences Center.
In an effort to be fair to all, NIH has been consistently applying its standards for application compliance. This consistency means that some applications recently have been rejected due to non-compliance. Issues that can lead NIH to reject an application include but are no limited to:
University of Kentucky Markey Cancer Center Oncologist Dr. Edward Romond spent his career at UK treating and studying breast cancer, even leading major Phase 3 clinical trials on the breast cancer drug trastuzumab in the early 2000s. Commonly known as Herceptin, this drug became a standard of care for patients with HER2-positive breast cancer.
Though he retired from practice last year, Romond continues to work part-time with the research team at Markey, this time pushing toward a cure for a different, more deadly, type of breast cancer.
